Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acusphere Inc. stock logo
ACUS
Acusphere
$0.00
$0.00
$0.00
N/A-1.87N/AN/A
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
$0.00
N/A7.341,891 shs200 shs
AOBI
American Oriental Bioengineering
$0.00
$0.00
$0.00
$0.00
N/A7.285 shsN/A
ARYX
ARYx Therapeutics
$0.00
$0.00
$0.00
N/A0.04N/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$10.55
+4.6%
$9.56
$8.06
$17.00
$134.89M1.6343,502 shs35,299 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acusphere Inc. stock logo
ACUS
Acusphere
0.00%0.00%0.00%0.00%+900.00%
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+700.00%-66.67%+14.29%
AOBI
American Oriental Bioengineering
0.00%0.00%0.00%0.00%0.00%
ARYX
ARYx Therapeutics
0.00%0.00%0.00%0.00%0.00%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.20%+11.49%+4.45%+7.00%-38.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/AN/AN/A
ARYX
ARYx Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.4796 of 5 stars
3.50.00.00.00.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acusphere Inc. stock logo
ACUS
Acusphere
0.00
N/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
AOBI
American Oriental Bioengineering
0.00
N/AN/AN/A
ARYX
ARYx Therapeutics
0.00
N/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00269.67% Upside

Current Analyst Ratings Breakdown

Latest GLSI, ACUS, AFFY, AOBI, and ARYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/AN/A
ARYX
ARYx Therapeutics
N/AN/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/A0.00N/AN/AN/AN/AN/A
ARYX
ARYx Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)

Latest GLSI, ACUS, AFFY, AOBI, and ARYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/AN/AN/A
ARYX
ARYx Therapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acusphere Inc. stock logo
ACUS
Acusphere
N/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/A
AOBI
American Oriental Bioengineering
N/AN/AN/A
ARYX
ARYx Therapeutics
N/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.91
1.91
CompanyEmployeesShares OutstandingFree FloatOptionable
Acusphere Inc. stock logo
ACUS
Acusphere
118N/AN/ANot Optionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
AOBI
American Oriental Bioengineering
3,720N/AN/ANot Optionable
ARYX
ARYx Therapeutics
56N/AN/ANot Optionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.46 millionNot Optionable

Recent News About These Companies

Greenwich LifeSciences provides update on FLAMINGO-01 trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acusphere stock logo

Acusphere OTCMKTS:ACUS

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 0.00 (0.00%)
As of 01:30 PM Eastern

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

American Oriental Bioengineering OTCMKTS:AOBI

$0.0005 0.00 (0.00%)
As of 07/3/2025

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.

ARYx Therapeutics OTCMKTS:ARYX

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$10.55 +0.46 (+4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$10.56 +0.01 (+0.09%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.